SRZN Surrozen, Inc.
Financings ·
Surrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029.
The second tranche brought in about $95.1 million gross, before placement agent fees, and the company expects cash to last into 2029. The first patient in its SZN-8141 trial is not expected to be dosed until the fourth quarter of 2026, after a rival Wnt drug met its primary endpoint in a Phase 2b/3 trial in the same eye disease.
FDA clearance of the SZN-8141 IND satisfies the second closing milestone in Surrozen's March 2025 private placement, which is expected to bring about $95.1 million gross on or about October 20, 2026. First patient dosing is not expected until the fourth quarter of 2026, with initial data in the second half of 2027.
Surrozen sold 6,586,415 units in a first closing on March 26, 2025, for about $76.4 million gross before fees. Placement agent Guggenheim Securities, LLC was named in the purchase agreement. A second closing of about $98.6 million depends on FDA clearance of the SZN-8141 IND by October 31, 2026.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.5 million | $10.7 million |
| Research and development | $29.4 million | $21.1 million |
| Net income (loss) | -$242.0 million | -$63.6 million |
| Cash from operations | -$30.2 million | -$17.6 million |
| Cash and equivalents | $89.2 million | $34.6 million |
Our latest story on this, dated Oct 20, 2026: "Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross". The story links the filing or release it is based on. Read the story.
Surrozen, Inc. trades under the ticker SRZN on NASDAQ.
Surrozen, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Surrozen, Inc. is 1824893. Its filings are on SEC EDGAR.
11,753,558 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Surrozen, Inc. under United States.
Our directory classifies Surrozen, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Surrozen, Inc. is US86889P2083.
aibio.space lists Surrozen, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$3.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Surrozen, Inc. reported a net loss of $242.0 million for the fiscal year ended Dec 31, 2025, and used $30.2 million of cash in operations, per its annual report to the SEC.
$29.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$102.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Surrozen, dated Oct 20, 2026: "Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross". Surrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.02,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio